Cargando…

PD-1 Immune Checkpoint Inhibitor Therapy Malignant Tumor Based on Monotherapy and Combined Treatment Research

Recently, immunotherapy has become the fourth pillar of cancer treatment in addition to surgery therapy, chemotherapy, and radiation therapy. The inhibitors of programed cell death protein 1 (PD-1) and its ligand PD-L1 are the new stars in immunotherapy, as they can overcome tumor immunosuppression....

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Yu, Mou, Guang-Ze, Li, Tian-Zhu, Xu, Wan-Ting, Zhang, Tong, Xue, Hui, Zuo, Wen-Bo, Li, Yan-Nan, Luo, Ying-Hua, Jin, Cheng-Hao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8093614/ https://www.ncbi.nlm.nih.gov/pubmed/33759637 http://dx.doi.org/10.1177/15330338211004942

Ejemplares similares

Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies
por: Wang, Dongxu, et al.
Publicado: (2019)

PD-1 Antibody Monotherapy for Malignant Melanoma: A Systematic Review and Meta-Analysis
por: Lin, Zhijuan, et al.
Publicado: (2016)

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
por: Liu, Jinhua, et al.
Publicado: (2021)

Tumor DNA methylation profiles correlate with response to anti-PD-1 immune checkpoint inhibitor monotherapy in sarcoma patients
por: Starzer, Angelika M, et al.
Publicado: (2021)

Controlling Nutritional Status (CONUT) Predicts Survival in Gastric Cancer Patients With Immune Checkpoint Inhibitor (PD-1/PD-L1) Outcomes
por: Chen, Li, et al.
Publicado: (2022)

Effectiveness of Immune Checkpoint Inhibitor with Anti-PD-1 Monotherapy or in Combination with Ipilimumab in Younger versus Older Adults with Advanced Melanoma
por: Woo, Taylor E., et al.
Publicado: (2023)

Corrigendum: Controlling nutritional status (CONUT) predicts survival in gastric cancer patients with immune checkpoint inhibitor (PD-1/PD-L1) outcomes
por: Chen, Li, et al.
Publicado: (2022)

Molecular underpinnings of exceptional response in primary malignant melanoma of the esophagus to anti-PD-1 monotherapy
por: Dai, Jie, et al.
Publicado: (2023)

Efficacy and Safety of Immune Checkpoint Inhibitors for Advanced Malignant Melanoma: A Meta-Analysis on Monotherapy Vs Combination Therapy
por: Pradeep, Jnaneshwari, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: Monotherapies and Combined Therapies
por: Ouyang, Tao, et al.
Publicado: (2022)

Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy
por: Rose, April A N, et al.
Publicado: (2021)

Real‐world data prognostic model of overall survival in patients with advanced NSCLC receiving anti‐PD‐1/PD‐L1 immune checkpoint inhibitors as second‐line monotherapy
por: Julian, Cristina, et al.
Publicado: (2022)

Anti-PD1 checkpoint inhibitor with or without chemotherapy for patients with recurrent and metastatic nasopharyngeal carcinoma
por: Jin, Ting, et al.
Publicado: (2020)

Anti-PD-1 checkpoint blockade monotherapy in the orthotopic GL261 glioma model: the devil is in the detail
por: Tritz, Zachariah P, et al.
Publicado: (2021)

Investigation of response factors for monotherapy with immune checkpoint inhibitors in non‐small cell lung cancer patients with PD‐L1 expression <50%
por: Takahara, Yutaka, et al.
Publicado: (2023)

Checkpoint inhibitors in hematological malignancies
por: Ok, Chi Young, et al.
Publicado: (2017)

Efficacy and safety of combination PD‐1/PD‐L1 checkpoint inhibitors for malignant solid tumours: A systematic review
por: Yao, Qigu, et al.
Publicado: (2020)

PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
por: Li, Qian, et al.
Publicado: (2022)

Real-World Outcomes and Clinical Predictors of Immune Checkpoint Inhibitor Monotherapy in Advanced Lung Cancer
por: Zhang, Shijia, et al.
Publicado: (2021)

Immune checkpoint blockade: the role of PD-1-PD-L axis in lymphoid malignancies
por: Ilcus, Cristina, et al.
Publicado: (2017)

Neurological adverse events associated with PD-1/PD-L1 immune checkpoint inhibitors
por: Zhou, Yanting, et al.
Publicado: (2023)

Risk Factors, Incidence, and Prognosis of Thromboembolism in Cancer Patients Treated With Immune Checkpoint Inhibitors
por: Zou, Xue-lin, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors as Monotherapy or Within a Combinatorial Strategy in Advanced Hepatocellular Carcinoma
por: Guardascione, Michela, et al.
Publicado: (2020)

Immune checkpoint inhibitor monotherapy is associated with less cardiac toxicity than combination therapy
por: Cone, Eugene B., et al.
Publicado: (2022)

Is Weak Acid Beneficial for Addressing Checkpoint Inhibitor–Triggered Cancer Hyper Progression in Anti-PD1/PD-L1 Immunotherapies?
por: Wan, Yulin, et al.
Publicado: (2020)

Prognostic Value of Neoantigen Load in Immune Checkpoint Inhibitor Therapy for Cancer
por: Zou, Xue-lin, et al.
Publicado: (2021)

Checkpoint inhibitors in the treatment of urological malignancies
por: Popovic, Lazar S, et al.
Publicado: (2017)

Mycobacterial infections due to PD-1 and PD-L1 checkpoint inhibitors
por: Anand, Kartik, et al.
Publicado: (2020)

PD-1 Checkpoint Inhibitor Associated Autoimmune Encephalitis
por: Schneider, Stephanie, et al.
Publicado: (2017)

Outcome differences between PD-1/PD-L1 inhibitors-based monotherapy and combination treatments in NSCLC with brain metastases
por: Wang, Haowei, et al.
Publicado: (2023)

A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy
por: Wang, Yuanyuan, et al.
Publicado: (2021)

The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers
por: Tang, Qing, et al.
Publicado: (2022)

Efficacy of immune-checkpoint inhibitors in PD-L1 selected or unselected patients vs. control group in patients with advanced or metastatic urothelial carcinoma
por: Guo, Lifang, et al.
Publicado: (2021)

Immune checkpoint inhibitor (ICI) combination therapy compared to monotherapy in advanced solid cancer: A systematic review
por: Ma, Xiaoting, et al.
Publicado: (2021)

Cognitive adverse events in patients with lung cancer treated with checkpoint inhibitor monotherapy: a propensity score-matched analysis
por: Ma, Yifei, et al.
Publicado: (2023)

Transarterial Chemoembolization Combined with Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors versus Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Advanced Hepatocellular Carcinoma
por: Huang, Jin-Tao, et al.
Publicado: (2022)

PD-L1 expression on malignant cells is no prerequisite for checkpoint therapy
por: Kleinovink, Jan Willem, et al.
Publicado: (2017)

Liver metastasis affects progression pattern during immune checkpoint inhibitors monotherapy in gastric cancer
por: Motoo, Iori, et al.
Publicado: (2023)

Distinct circulating cytokine/chemokine profiles correlate with clinical benefit of immune checkpoint inhibitor monotherapy and combination therapy in advanced non‐small cell lung cancer
por: Hu, Yue, et al.
Publicado: (2023)

Case Report: Acute Myocarditis Due to PD-L1 Inhibitor Durvalumab Monotherapy in a Patient With Lung Squamous Cell Carcinoma
por: Zhou, Bo, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3pbcntk9f0kk4pna2vjlhabugc